Genentech @genentech · 02 Jul 2026
#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51 https://t.co/rtrg18njSj
6 353Views
10Likes
4Reposts
1Replies
1Quotes
0Bookmarks
Is that a lot?
2.39×vs this author's median2 660 views is typical
80Percentile for this authorof 5 recent posts
0.33×vs 100K–1M median19 302 views is typical
5.16%Reachviews ÷ followers
0.25%Engagement rateof viewers reacted